Print this page    •   Back to Web version of article

Options for People With Multi-Drug Resistance

Spring 2006

Activists have long pushed for clinical trials that combine two new drugs for people who have no active agents, and one company, Tibotec, has recently begun the first such trials, of a protease inhibitor, darunavir (TMC 114), and an NNRTI, etravirine (TMC 125).

The DUET studies allow patients to take both of these drugs, although people will be randomized to receive etravirine or placebo. So there still is a 50% chance of receiving virtual monotherapy if you have no other active drugs available. (People randomized to receive only darunavir can add etravirine after 6 months if their viral load is not controlled.)

If your genotype test shows that your HIV is resistant to most approved anti-HIV drugs and you and your health care provider feel you must change your regimen, here are some options. (Not everyone who is resistant to their meds needs to switch; there may be good reasons not to.)

Back to the ACRIA Update Spring 2006 contents page.

This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.